Alternative IP Mechanisms in Genomic Research
Identifieur interne : 000338 ( Istex/Corpus ); précédent : 000337; suivant : 000339Alternative IP Mechanisms in Genomic Research
Auteurs : Cheryl Power ; Ed Levy ; Emily Marden ; Ben WarrenSource :
- Studies in Ethics, Law, and Technology [ 1941-6008 ] ; 2008.
English descriptors
- Teeft :
- Academic technology transfer landscape, Alternative mechanisms, Available website, Biological targets, Biomedical research, British columbia, British columbia cancer agency, Broader access, Broader study, Carolina journal, Case study, Cell therapies, Commercialization, Commonwealth department, Complex situation, Creative commons, Discovery space, Efficient identification, Funding, Gene expression, Gene expression networks, Gene patenting, Genome, Genome canada, Genome canada data release policy, Genome canada policies, Genomic, Genomic research, Genomic research cheryl power, Genomics, Genomics research, Human gene patenting controversies, Independent voice, Intellectual property, Interim conclusions, Legal framework, Mammalian organogenesis project, Mouse atlas, National congress, National development, Nature biotechnology, Nematode caenorhabditis elegans, Online, Open science, Open source, Open source licenses, Open source philosophies, Organogenesis, Patent ownership, Patent pool, Patent pools, Patenting, Public domain, Research institutions, Research issues, Research results, Science training, Scientific research, Simon fraser university, Single gene deletions, Social issues, Special focus, Such approaches, Technology transfer, Technology transfer offices, University industry liaison office, Useful applications, Website.
Abstract
This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.
Url:
DOI: 10.2202/1941-6008.1052
Links to Exploration step
ISTEX:255956A39B64306BA111799D5F8C32E1F7EE943DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Alternative IP Mechanisms in Genomic Research</title><author><name sortKey="Power, Cheryl" sort="Power, Cheryl" uniqKey="Power C" first="Cheryl" last="Power">Cheryl Power</name><affiliation><mods:affiliation>LLM</mods:affiliation></affiliation></author><author><name sortKey="Levy, Ed" sort="Levy, Ed" uniqKey="Levy E" first="Ed" last="Levy">Ed Levy</name><affiliation><mods:affiliation>University of British Columbia</mods:affiliation></affiliation></author><author><name sortKey="Marden, Emily" sort="Marden, Emily" uniqKey="Marden E" first="Emily" last="Marden">Emily Marden</name><affiliation><mods:affiliation>University of British Columbia</mods:affiliation></affiliation></author><author><name sortKey="Warren, Ben" sort="Warren, Ben" uniqKey="Warren B" first="Ben" last="Warren">Ben Warren</name><affiliation><mods:affiliation>University of British Columbia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:255956A39B64306BA111799D5F8C32E1F7EE943D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.2202/1941-6008.1052</idno><idno type="url">https://api.istex.fr/ark:/67375/QT4-L4HFB9TF-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000338</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000338</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Alternative IP Mechanisms in Genomic Research</title><author><name sortKey="Power, Cheryl" sort="Power, Cheryl" uniqKey="Power C" first="Cheryl" last="Power">Cheryl Power</name><affiliation><mods:affiliation>LLM</mods:affiliation></affiliation></author><author><name sortKey="Levy, Ed" sort="Levy, Ed" uniqKey="Levy E" first="Ed" last="Levy">Ed Levy</name><affiliation><mods:affiliation>University of British Columbia</mods:affiliation></affiliation></author><author><name sortKey="Marden, Emily" sort="Marden, Emily" uniqKey="Marden E" first="Emily" last="Marden">Emily Marden</name><affiliation><mods:affiliation>University of British Columbia</mods:affiliation></affiliation></author><author><name sortKey="Warren, Ben" sort="Warren, Ben" uniqKey="Warren B" first="Ben" last="Warren">Ben Warren</name><affiliation><mods:affiliation>University of British Columbia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Studies in Ethics, Law, and Technology</title><idno type="eISSN">1941-6008</idno><imprint><publisher>De Gruyter</publisher><date type="e-published">2008</date><biblScope unit="vol">2</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page-count">13</biblScope></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Academic technology transfer landscape</term><term>Alternative mechanisms</term><term>Available website</term><term>Biological targets</term><term>Biomedical research</term><term>British columbia</term><term>British columbia cancer agency</term><term>Broader access</term><term>Broader study</term><term>Carolina journal</term><term>Case study</term><term>Cell therapies</term><term>Commercialization</term><term>Commonwealth department</term><term>Complex situation</term><term>Creative commons</term><term>Discovery space</term><term>Efficient identification</term><term>Funding</term><term>Gene expression</term><term>Gene expression networks</term><term>Gene patenting</term><term>Genome</term><term>Genome canada</term><term>Genome canada data release policy</term><term>Genome canada policies</term><term>Genomic</term><term>Genomic research</term><term>Genomic research cheryl power</term><term>Genomics</term><term>Genomics research</term><term>Human gene patenting controversies</term><term>Independent voice</term><term>Intellectual property</term><term>Interim conclusions</term><term>Legal framework</term><term>Mammalian organogenesis project</term><term>Mouse atlas</term><term>National congress</term><term>National development</term><term>Nature biotechnology</term><term>Nematode caenorhabditis elegans</term><term>Online</term><term>Open science</term><term>Open source</term><term>Open source licenses</term><term>Open source philosophies</term><term>Organogenesis</term><term>Patent ownership</term><term>Patent pool</term><term>Patent pools</term><term>Patenting</term><term>Public domain</term><term>Research institutions</term><term>Research issues</term><term>Research results</term><term>Science training</term><term>Scientific research</term><term>Simon fraser university</term><term>Single gene deletions</term><term>Social issues</term><term>Special focus</term><term>Such approaches</term><term>Technology transfer</term><term>Technology transfer offices</term><term>University industry liaison office</term><term>Useful applications</term><term>Website</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.</div></front></TEI><istex><corpusName>degruyter-journals</corpusName><keywords><teeft><json:string>genome</json:string><json:string>online</json:string><json:string>genome canada</json:string><json:string>genomics</json:string><json:string>british columbia</json:string><json:string>genomic</json:string><json:string>commercialization</json:string><json:string>open science</json:string><json:string>organogenesis</json:string><json:string>patenting</json:string><json:string>website</json:string><json:string>funding</json:string><json:string>open source</json:string><json:string>legal framework</json:string><json:string>genomic research</json:string><json:string>intellectual property</json:string><json:string>social issues</json:string><json:string>british columbia cancer agency</json:string><json:string>research results</json:string><json:string>gene expression</json:string><json:string>technology transfer offices</json:string><json:string>mouse atlas</json:string><json:string>genome canada policies</json:string><json:string>alternative mechanisms</json:string><json:string>cell therapies</json:string><json:string>gene expression networks</json:string><json:string>public domain</json:string><json:string>patent pools</json:string><json:string>genomics research</json:string><json:string>creative commons</json:string><json:string>simon fraser university</json:string><json:string>biological targets</json:string><json:string>special focus</json:string><json:string>broader study</json:string><json:string>genomic research cheryl power</json:string><json:string>discovery space</json:string><json:string>broader access</json:string><json:string>case study</json:string><json:string>complex situation</json:string><json:string>useful applications</json:string><json:string>independent voice</json:string><json:string>gene patenting</json:string><json:string>mammalian organogenesis project</json:string><json:string>interim conclusions</json:string><json:string>technology transfer</json:string><json:string>biomedical research</json:string><json:string>human gene patenting controversies</json:string><json:string>nature biotechnology</json:string><json:string>academic technology transfer landscape</json:string><json:string>national congress</json:string><json:string>national development</json:string><json:string>commonwealth department</json:string><json:string>science training</json:string><json:string>patent ownership</json:string><json:string>research institutions</json:string><json:string>genome canada data release policy</json:string><json:string>university industry liaison office</json:string><json:string>open source licenses</json:string><json:string>scientific research</json:string><json:string>carolina journal</json:string><json:string>research issues</json:string><json:string>open source philosophies</json:string><json:string>efficient identification</json:string><json:string>single gene deletions</json:string><json:string>nematode caenorhabditis elegans</json:string><json:string>such approaches</json:string><json:string>patent pool</json:string><json:string>available website</json:string></teeft></keywords><author><json:item><name>Cheryl Power</name><affiliations><json:string>LLM</json:string></affiliations></json:item><json:item><name>Ed Levy</name><affiliations><json:string>University of British Columbia</json:string></affiliations></json:item><json:item><name>Emily Marden</name><affiliations><json:string>University of British Columbia</json:string></affiliations></json:item><json:item><name>Ben Warren</name><affiliations><json:string>University of British Columbia</json:string></affiliations></json:item></author><articleId><json:string>1941-6008.1052</json:string></articleId><arkIstex>ark:/67375/QT4-L4HFB9TF-F</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.</abstract><qualityIndicators><score>8.173</score><pdfWordCount>4013</pdfWordCount><pdfCharCount>26760</pdfCharCount><pdfVersion>1.6</pdfVersion><pdfPageCount>13</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>180</abstractWordCount><abstractCharCount>1211</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Alternative IP Mechanisms in Genomic Research</title><genre><json:string>research-article</json:string></genre><host><title>Studies in Ethics, Law, and Technology</title><language><json:string>unknown</json:string></language><publicationDate>2008</publicationDate><copyrightDate>2011</copyrightDate><eissn><json:string>1941-6008</json:string></eissn><publisherId><json:string>selt</json:string></publisherId><volume>2</volume><issue>2</issue><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date></date><geogName></geogName><orgName></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/QT4-L4HFB9TF-F</json:string></ark><categories><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - generalites</json:string></inist></categories><publicationDate>2008</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.2202/1941-6008.1052</json:string></doi><id>255956A39B64306BA111799D5F8C32E1F7EE943D</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/QT4-L4HFB9TF-F/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/QT4-L4HFB9TF-F/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/QT4-L4HFB9TF-F/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Alternative IP Mechanisms in Genomic Research</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>De Gruyter</publisher><availability><licence>©2011 Walter de Gruyter GmbH & Co. KG, Berlin/Boston</licence></availability><date type="e-published">2008</date><date type="Copyright" when="2011">2011</date></publicationStmt><notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Alternative IP Mechanisms in Genomic Research</title><author xml:id="author-0000"><persName><surname>Power</surname><forename type="first">Cheryl</forename></persName><affiliation>
LLM
</affiliation></author><author xml:id="author-0001"><persName><surname>Levy</surname><forename type="first">Ed</forename></persName><affiliation>
University of British Columbia
</affiliation></author><author xml:id="author-0002"><persName><surname>Marden</surname><forename type="first">Emily</forename></persName><affiliation>
University of British Columbia
</affiliation></author><author xml:id="author-0003"><persName><surname>Warren</surname><forename type="first">Ben</forename></persName><affiliation>
University of British Columbia
</affiliation></author><idno type="istex">255956A39B64306BA111799D5F8C32E1F7EE943D</idno><idno type="ark">ark:/67375/QT4-L4HFB9TF-F</idno><idno type="publisher-id">1941-6008.1052</idno><idno type="DOI">10.2202/1941-6008.1052</idno></analytic><monogr><title level="j" type="main">Studies in Ethics, Law, and Technology</title><idno type="publisher-id">selt</idno><idno type="eISSN">1941-6008</idno><imprint><publisher>De Gruyter</publisher><date type="e-published">2008</date><biblScope unit="vol">2</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page-count">13</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.38" when="2020-03-09"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract><p>This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>Article</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc><revisionDesc><change when="2020-03-09" who="#istex" xml:id="pub2tei">formatting</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2020-03-11">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/QT4-L4HFB9TF-F/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus degruyter-journals" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Atypon//DTD Atypon Systems Journal Archiving and Interchange NLM DTD v3.0.2 20101108//EN" URI="atypon_archive-interchange-dtd-3.0.2/atypon-archivearticle3.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article" dtd-version="3.0" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="publisher-id">selt</journal-id><journal-title-group><journal-title>Studies in Ethics, Law, and Technology</journal-title></journal-title-group><issn pub-type="epub">1941-6008</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1941-6008.1052</article-id><article-id pub-id-type="doi">10.2202/1941-6008.1052</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Alternative IP Mechanisms in Genomic Research</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Power</surname><given-names>Cheryl</given-names></name><aff id="a1"><italic>LLM</italic></aff></contrib><contrib contrib-type="author"><name><surname>Levy</surname><given-names>Ed</given-names></name><aff id="a2"><italic>University of British Columbia</italic></aff></contrib><contrib contrib-type="author"><name><surname>Marden</surname><given-names>Emily</given-names></name><aff id="a3"><italic>University of British Columbia</italic></aff></contrib><contrib contrib-type="author"><name><surname>Warren</surname><given-names>Ben</given-names></name><aff id="a4"><italic>University of British Columbia</italic></aff></contrib></contrib-group><pub-date pub-type="epub"><day>26</day><month>8</month><year>2008</year></pub-date><volume>2</volume><issue>2</issue><permissions><copyright-statement>©2011 Walter de Gruyter GmbH & Co. KG, Berlin/Boston</copyright-statement><copyright-year>2011</copyright-year></permissions><related-article related-article-type="pdf" xlink:href="selt.2008.2.2.1052.pdf"></related-article><abstract><p>This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.</p></abstract><counts><page-count count="13"></page-count></counts></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Alternative IP Mechanisms in Genomic Research</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Alternative IP Mechanisms in Genomic Research</title></titleInfo><name type="personal"><namePart type="given">Cheryl</namePart><namePart type="family">Power</namePart><affiliation>LLM</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ed</namePart><namePart type="family">Levy</namePart><affiliation>University of British Columbia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Emily</namePart><namePart type="family">Marden</namePart><affiliation>University of British Columbia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ben</namePart><namePart type="family">Warren</namePart><affiliation>University of British Columbia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>De Gruyter</publisher><dateIssued encoding="w3cdtf">2008-08-26</dateIssued><dateCreated encoding="w3cdtf">2008-08-26</dateCreated><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.</abstract><relatedItem type="host"><titleInfo><title>Studies in Ethics, Law, and Technology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>De Gruyter</publisher><dateIssued encoding="w3cdtf">2008-08-26</dateIssued><dateCreated encoding="w3cdtf">2008-08-26</dateCreated><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><identifier type="eISSN">1941-6008</identifier><identifier type="PublisherID">selt</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><total>13</total></extent></part></relatedItem><identifier type="istex">255956A39B64306BA111799D5F8C32E1F7EE943D</identifier><identifier type="ark">ark:/67375/QT4-L4HFB9TF-F</identifier><identifier type="DOI">10.2202/1941-6008.1052</identifier><identifier type="ArticleID">1941-6008.1052</identifier><identifier type="pdf">selt.2008.2.2.1052.pdf</identifier><accessCondition type="use and reproduction" contentType="copyright">©2011 Walter de Gruyter GmbH & Co. KG, Berlin/Boston</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-B4QPMMZB-D">degruyter-journals</recordContentSource><recordOrigin>Converted from (version 1.2.5) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2020-02-05</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/QT4-L4HFB9TF-F/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000338 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000338 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:255956A39B64306BA111799D5F8C32E1F7EE943D
|texte= Alternative IP Mechanisms in Genomic Research
}}
| This area was generated with Dilib version V0.6.33. |  |